{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:31:36Z","timestamp":1793791896025,"version":"4.6.1"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Currently, those recommended to undergo pancreatic cancer (PC) surveillance include appropriately aged individuals at high risk of PC due to an identifiable genetic susceptibility or those without identifiable genetic susceptibility who nonetheless have a strong family history of PC. With increases in identification of individuals at high risk for PC and increased use of PC surveillance in clinical practice, there has been increasing debate about who should undergo surveillance as well as how surveillance should be performed including use of imaging and blood-based testing. Furthermore, there is increasing interest in the outcomes of PC surveillance in high-risk individuals with some studies demonstrating that surveillance leads to downstaging of PC and improvements in survival. In this review, we summarize the current state of PC surveillance in high-risk individuals, providing an overview of the risk factors associated with PC, selection of high-risk individuals for PC surveillance, and the current, but non-uniform, recommendations for performing PC surveillance. Additionally, we review approaches to apply various imaging and blood-based tests to surveillance and the outcomes of PC surveillance.<\/jats:p>","DOI":"10.1007\/s12029-025-01184-1","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T16:32:11Z","timestamp":1739291531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current Approaches of Pancreatic Cancer Surveillance in High-Risk Individuals"],"prefix":"10.1007","volume":"56","author":[{"given":"Melissa","family":"Heller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryson W.","family":"Katona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"1","key":"1184_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1184_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.gastro.2023.01.022","volume":"164","author":"Y Abboud","year":"2023","unstructured":"Abboud Y, et al. Increasing pancreatic cancer incidence in young women in the United States: a population-based time-trend analysis, 2001\u20132018. Gastroenterology. 2023;164(6):978-989.e6.","journal-title":"Gastroenterology"},{"issue":"32","key":"1184_CR3","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.3748\/wjg.v28.i32.4698","volume":"28","author":"I Ilic","year":"2022","unstructured":"Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis. World J Gastroenterol. 2022;28(32):4698\u2013715.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1184_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology. 2023;164(5):752\u201365.","journal-title":"Gastroenterology"},{"issue":"11","key":"1184_CR5","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jnci\/djaa004","volume":"112","author":"AL Blackford","year":"2020","unstructured":"Blackford AL, et al. Recent trends in the incidence and survival of Stage 1A pancreatic cancer: a surveillance, epidemiology, and end results analysis. J Natl Cancer Inst. 2020;112(11):1162\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"1184_CR6","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu C, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401\u20139.","journal-title":"JAMA"},{"issue":"30","key":"1184_CR7","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","volume":"35","author":"K Shindo","year":"2017","unstructured":"Shindo K, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382\u201390.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1184_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","volume":"21","author":"MB Yurgelun","year":"2019","unstructured":"Yurgelun MB, et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019;21(1):213\u201323.","journal-title":"Genet Med"},{"issue":"6","key":"1184_CR9","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.3390\/cancers15061852","volume":"15","author":"A Dal Buono","year":"2023","unstructured":"Dal Buono A, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer or suspected related hereditary syndromes: historical prospective analysis. Cancers (Basel). 2023;15(6):1852.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1184_CR10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer CE Jr, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250\u201368.","journal-title":"Ann Oncol"},{"issue":"4","key":"1184_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, et al. Maintenance olaparib for germline brca-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med"},{"key":"1184_CR12","doi-asserted-by":"crossref","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast, o., and pancreatic. Version 1.2025\u2014September 11, 2024. [cited 2024 Sept 13]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf.","DOI":"10.47429\/lmo.2025.15.1.11"},{"issue":"34","key":"1184_CR13","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1200\/JCO.2016.67.0554","volume":"34","author":"KN Maxwell","year":"2016","unstructured":"Maxwell KN, et al. Population frequency of germline BRCA1\/2 mutations. J Clin Oncol. 2016;34(34):4183\u20135.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1184_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","volume":"40","author":"S Li","year":"2022","unstructured":"Li S, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529\u201341.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1184_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jmg.2004.028829","volume":"42","author":"CJ van Asperen","year":"2005","unstructured":"van Asperen CJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42(9):711\u20139.","journal-title":"J Med Genet"},{"key":"1184_CR16","doi-asserted-by":"crossref","unstructured":"Katona BW, et al. The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation. Cancer. 2025;131(1):e35666.","DOI":"10.1002\/cncr.35666"},{"issue":"7","key":"1184_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang X, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020;38(7):674\u201385.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1184_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10689-018-00117-1","volume":"18","author":"LH Biller","year":"2019","unstructured":"Biller LH, Syngal S, Yurgelun MB. Recent advances in Lynch syndrome. Fam Cancer. 2019;18(2):211\u20139.","journal-title":"Fam Cancer"},{"key":"1184_CR19","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: colon, e.a.g.V.A., 2024. [cited 2024 Sept 13]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_ceg.pdf."},{"issue":"7","key":"1184_CR20","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","volume":"67","author":"P M\u00f8ller","year":"2018","unstructured":"M\u00f8ller P, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2018;67(7):1306\u201316.","journal-title":"Gut"},{"issue":"11","key":"1184_CR21","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1001\/jamaoncol.2021.3701","volume":"7","author":"FC Hsu","year":"2021","unstructured":"Hsu FC, et al. Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene. JAMA Oncol. 2021;7(11):1664\u20138.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1184_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MOG.0000000000000718","volume":"37","author":"I Tacheci","year":"2021","unstructured":"Tacheci I, Kopacova M, Bures J. Peutz-Jeghers syndrome. Curr Opin Gastroenterol. 2021;37(3):245\u201354.","journal-title":"Curr Opin Gastroenterol"},{"issue":"6","key":"1184_CR23","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1053\/gast.2000.20228","volume":"119","author":"FM Giardiello","year":"2000","unstructured":"Giardiello FM, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119(6):1447\u201353.","journal-title":"Gastroenterology"},{"issue":"6","key":"1184_CR24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/ajg.2009.725","volume":"105","author":"MG van Lier","year":"2010","unstructured":"van Lier MG, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105(6):1258\u201364.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1184_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/bjd.14485","volume":"175","author":"MR Sargen","year":"2016","unstructured":"Sargen MR, et al. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature. Br J Dermatol. 2016;175(4):785\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1184_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/1097-0215(20000915)87:6<809::AID-IJC8>3.0.CO;2-U","volume":"87","author":"HF Vasen","year":"2000","unstructured":"Vasen HF, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87(6):809\u201311.","journal-title":"Int J Cancer"},{"issue":"1","key":"1184_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.giec.2021.08.006","volume":"32","author":"Y Fu","year":"2022","unstructured":"Fu Y, Lucas AL. Genetic evaluation of pancreatitis. Gastrointest Endosc Clin N Am. 2022;32(1):27\u201343.","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"1184_CR28","doi-asserted-by":"crossref","unstructured":"Greenhalf W et al. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. Pancreatology. 2020;20(5): 910\u2013918.","DOI":"10.1016\/j.pan.2020.05.011"},{"issue":"9","key":"1184_CR29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41395-018-0194-5","volume":"113","author":"CA Shelton","year":"2018","unstructured":"Shelton CA, et al. Hereditary pancreatitis in the United States: survival and rates of pancreatic cancer. Am J Gastroenterol. 2018;113(9):1376.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1184_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/gepi.21644","volume":"36","author":"BL Pierce","year":"2012","unstructured":"Pierce BL, et al. Unidentified genetic variants influence pancreatic cancer risk: an analysis of polygenic susceptibility in the PanScan study. Genet Epidemiol. 2012;36(5):517\u201324.","journal-title":"Genet Epidemiol"},{"issue":"3","key":"1184_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.gtc.2022.06.006","volume":"51","author":"H Saba","year":"2022","unstructured":"Saba H, Goggins M. Familial pancreatic cancer. Gastroenterol Clin North Am. 2022;51(3):561\u201375.","journal-title":"Gastroenterol Clin North Am"},{"key":"1184_CR32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CMAR.S172421","volume":"12","author":"J Llach","year":"2020","unstructured":"Llach J, Carballal S, Moreira L. Familial pancreatic cancer: current perspectives. Cancer Manag Res. 2020;12:743\u201358.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"1184_CR33","doi-asserted-by":"publisher","first-page":"102079","DOI":"10.1016\/j.clinre.2023.102079","volume":"47","author":"L Del Nero","year":"2023","unstructured":"Del Nero L, et al. Familial pancreatic cancer. Clin Res Hepatol Gastroenterol. 2023;47(3):102079.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"1184_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00423-007-0266-2","volume":"393","author":"S Iodice","year":"2008","unstructured":"Iodice S, et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393(4):535\u201345.","journal-title":"Langenbecks Arch Surg"},{"issue":"5","key":"1184_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bpg.2017.09.001","volume":"31","author":"M Korc","year":"2017","unstructured":"Korc M, et al. Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2017;31(5):529\u201336.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"7","key":"1184_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493\u2013502.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1184_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/ije\/dyu240","volume":"44","author":"P Maisonneuve","year":"2015","unstructured":"Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44(1):186\u201398.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"1184_CR38","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/annonc\/mdr120","volume":"23","author":"E Lucenteforte","year":"2012","unstructured":"Lucenteforte E, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012;23(2):374\u201382.","journal-title":"Ann Oncol"},{"issue":"4","key":"1184_CR39","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3945\/ajcn.113.058123","volume":"98","author":"RZ Stolzenberg-Solomon","year":"2013","unstructured":"Stolzenberg-Solomon RZ, et al. Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. Am J Clin Nutr. 2013;98(4):1057\u201365.","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"1184_CR40","doi-asserted-by":"publisher","first-page":"e001362","DOI":"10.3945\/cdn.117.001362","volume":"1","author":"L Nogueira","year":"2017","unstructured":"Nogueira L, et al. Childhood body mass index and risk of adult pancreatic cancer. Curr Dev Nutr. 2017;1(10):e001362.","journal-title":"Curr Dev Nutr"},{"issue":"8","key":"1184_CR41","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1001\/jama.286.8.921","volume":"286","author":"DS Michaud","year":"2001","unstructured":"Michaud DS, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001;286(8):921\u20139.","journal-title":"JAMA"},{"issue":"12","key":"1184_CR42","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1002\/cam4.3958","volume":"10","author":"AJ Farias","year":"2021","unstructured":"Farias AJ, et al. Racial\/ethnic disparities in weight or BMI change in adulthood and pancreatic cancer incidence: the multiethnic cohort. Cancer Med. 2021;10(12):4097\u2013106.","journal-title":"Cancer Med"},{"issue":"10","key":"1184_CR43","doi-asserted-by":"publisher","first-page":"e202948","DOI":"10.1001\/jamaoncol.2020.2948","volume":"6","author":"C Yuan","year":"2020","unstructured":"Yuan C, et al. Diabetes, weight change, and pancreatic cancer risk. JAMA Oncol. 2020;6(10):e202948.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1184_CR44","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.2337\/dc20-0204","volume":"43","author":"S Ling","year":"2020","unstructured":"Ling S, et al. Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people. Diabetes Care. 2020;43(9):2313\u201322.","journal-title":"Diabetes Care"},{"issue":"30","key":"1184_CR45","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.3748\/wjg.v27.i30.4939","volume":"27","author":"A Roy","year":"2021","unstructured":"Roy A, et al. Diabetes and pancreatic cancer: exploring the two-way traffic. World J Gastroenterol. 2021;27(30):4939\u201362.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1184_CR46","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.gastro.2005.05.007","volume":"129","author":"ST Chari","year":"2005","unstructured":"Chari ST, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504\u201311.","journal-title":"Gastroenterology"},{"issue":"4","key":"1184_CR47","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1053\/j.gastro.2008.01.039","volume":"134","author":"R Pannala","year":"2008","unstructured":"Pannala R, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981\u20137.","journal-title":"Gastroenterology"},{"issue":"12","key":"1184_CR48","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/aje\/kwv290","volume":"183","author":"R Dankner","year":"2016","unstructured":"Dankner R, et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183(12):1098\u2013106.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"1184_CR49","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1245\/s10434-014-3625-6","volume":"21","author":"P Batabyal","year":"2014","unstructured":"Batabyal P, et al. Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Ann Surg Oncol. 2014;21(7):2453\u201362.","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"1184_CR50","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.ejca.2011.03.003","volume":"47","author":"Q Ben","year":"2011","unstructured":"Ben Q, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928\u201337.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1184_CR51","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.cgh.2019.11.043","volume":"18","author":"BZ Huang","year":"2020","unstructured":"Huang BZ, et al. New-onset diabetes, longitudinal trends in metabolic markers, and risk of pancreatic cancer in a heterogeneous population. Clin Gastroenterol Hepatol. 2020;18(8):1812-1821.e7.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1184_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/jnci\/djy090","volume":"111","author":"VW Setiawan","year":"2019","unstructured":"Setiawan VW, et al. Pancreatic cancer following incident diabetes in African Americans and Latinos: the multiethnic cohort. J Natl Cancer Inst. 2019;111(1):27\u201333.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1184_CR53","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1136\/gut.2006.108456","volume":"56","author":"RE Brand","year":"2007","unstructured":"Brand RE, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut. 2007;56(10):1460\u20139.","journal-title":"Gut"},{"issue":"9","key":"1184_CR54","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.dld.2010.04.016","volume":"42","author":"M Del Chiaro","year":"2010","unstructured":"Del Chiaro M, et al. Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: a position paper from the Italian Registry. Dig Liver Dis. 2010;42(9):597\u2013605.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"1184_CR55","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/gutjnl-2012-303108","volume":"62","author":"MI Canto","year":"2013","unstructured":"Canto MI, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339\u201347.","journal-title":"Gut"},{"issue":"9","key":"1184_CR56","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.14309\/ajg.0000000000002314","volume":"118","author":"I Shah","year":"2023","unstructured":"Shah I, et al. Pancreatic Cancer screening for at-risk individuals (pancreas scan study): yield, harms, and outcomes from a prospective multicenter study. Off J Am College Gastroenterol ACG. 2023;118(9):1664\u201370.","journal-title":"Off J Am College Gastroenterol ACG"},{"issue":"5","key":"1184_CR57","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jama.2019.10232","volume":"322","author":"DK Owens","year":"2019","unstructured":"Owens DK, et al. Screening for pancreatic cancer: US preventive services task force reaffirmation recommendation statement. JAMA. 2019;322(5):438\u201344.","journal-title":"JAMA"},{"issue":"1","key":"1184_CR58","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.gastro.2020.03.088","volume":"159","author":"HR Aslanian","year":"2020","unstructured":"Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020;159(1):358\u201362.","journal-title":"Gastroenterology"},{"issue":"5","key":"1184_CR59","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.gie.2021.12.001","volume":"95","author":"MS Sawhney","year":"2022","unstructured":"Sawhney MS, et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc. 2022;95(5):817\u201326.","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"1184_CR60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","volume":"69","author":"M Goggins","year":"2020","unstructured":"Goggins M, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7\u201317.","journal-title":"Gut"},{"issue":"11","key":"1184_CR61","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(11):987\u20131002.","journal-title":"Ann Oncol"},{"issue":"28","key":"1184_CR62","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1200\/JCO.22.01287","volume":"40","author":"MB Yurgelun","year":"2022","unstructured":"Yurgelun MB. Building on more than 20 years of progress in pancreatic cancer surveillance for high-risk individuals. J Clin Oncol. 2022;40(28):3230\u20134.","journal-title":"J Clin Oncol"},{"issue":"28","key":"1184_CR63","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1200\/JCO.22.00194","volume":"40","author":"DCF Klatte","year":"2022","unstructured":"Klatte DCF, et al. Pancreatic cancer surveillance in carriers of a germline CDKN2A pathogenic variant: yield and outcomes of a 20-year prospective follow-up. J Clin Oncol. 2022;40(28):3267\u201377.","journal-title":"J Clin Oncol"},{"issue":"28","key":"1184_CR64","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1200\/JCO.22.00298","volume":"40","author":"M Dbouk","year":"2022","unstructured":"Dbouk M, et al. The multicenter cancer of pancreas screening study: impact on stage and survival. J Clin Oncol. 2022;40(28):3257\u201366.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1184_CR65","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3390\/cancers14102539","volume":"14","author":"KP Farr","year":"2022","unstructured":"Farr KP, et al. Imaging modalities for early detection of pancreatic cancer: current state and future research opportunities. Cancers (Basel). 2022;14(10):2539.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1184_CR66","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2214\/AJR.22.27859","volume":"219","author":"C Huang","year":"2022","unstructured":"Huang C, et al. Standardization of MRI screening and reporting in individuals with elevated risk of pancreatic ductal adenocarcinoma: consensus statement of the PRECEDE Consortium. AJR Am J Roentgenol. 2022;219(6):903\u201314.","journal-title":"AJR Am J Roentgenol"},{"key":"1184_CR67","unstructured":"University, J.H. The Cancer of the Pancreas Screening-5 CAPS5) study (CAPS5). 2024 [cited 2024 23 September]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT02000089?term=NCT02000089%0ANCT02478892%0ANCT03250078%0ANCT04970056%0ANCT05006131%0ANCT05058846%0ANCT06122896&rank=7."},{"key":"1184_CR68","unstructured":"Medicine, A.C.C.a.P. Preliminary evaluation of screening for pancreatic cancer in patients with inherited genetic risk. 2015 8\/26\/2024 [cited 2024 23 September]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT02478892."},{"key":"1184_CR69","unstructured":"Fran, R. A pancreatic cancer screening study in hereditary high risk individuals. 2016 [cited 2024 23 September]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT03250078."},{"key":"1184_CR70","unstructured":"Health ARCf. PRECEDE: pancreatic cancer early detection consortium. 2020 2024-12-20 [cited 2024 23 September]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT04970056."},{"key":"1184_CR71","unstructured":"Sawhney MS. Pancreas scan: pancreatic cancer screening for at-risk individuals. 2020 [cited 2024 23 September]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT05006131."},{"key":"1184_CR72","unstructured":"University of California, S.F. Pilot study of pancreatic cancer screening. 2024 [cited 2025 6 January]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT05058846?term=NCT02000089%0ANCT02478892%0ANCT03250078%0ANCT04970056%0ANCT05006131%0ANCT05058846%0ANCT06122896&rank=2."},{"key":"1184_CR73","unstructured":"Yurgelun MB. Prospective screening for pancreatic ductal adenocarcinoma in high-risk individuals. 2024 2\/28\/2024 [cited 2025 1\/6\/2025]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT06122896?cond=pancreatic%20cancer%20screening&rank=11."},{"issue":"6","key":"1184_CR74","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/gutjnl-2020-323611","volume":"71","author":"KA Overbeek","year":"2022","unstructured":"Overbeek KA, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71(6):1152\u201360.","journal-title":"Gut"},{"issue":"4","key":"1184_CR75","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3390\/cancers14041000","volume":"14","author":"S Kumar","year":"2022","unstructured":"Kumar S, et al. Upper gastrointestinal cancer surveillance in Lynch syndrome. Cancers (Basel). 2022;14(4):1000.","journal-title":"Cancers (Basel)"},{"key":"1184_CR76","doi-asserted-by":"crossref","unstructured":"Yamamiya A, et al. Interobserver reliability of endoscopic ultrasonography: literature review. Diagnostics (Basel). 2020;10(11).","DOI":"10.3390\/diagnostics10110953"},{"issue":"2","key":"1184_CR77","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/jmri.27148","volume":"53","author":"KA Harrington","year":"2021","unstructured":"Harrington KA, et al. MRI of the pancreas. J Magn Reson Imaging. 2021;53(2):347\u201359.","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"1184_CR78","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.mric.2007.06.005","volume":"15","author":"RR Edelman","year":"2007","unstructured":"Edelman RR. MR imaging of the pancreas: 1.5T versus 3T. Magn Reson Imaging Clin N Am. 2007;15(3):349\u201353.","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"9","key":"1184_CR79","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/RLI.0b013e3181b4c0ae","volume":"44","author":"H Onishi","year":"2009","unstructured":"Onishi H, et al. MR cholangiopancreatography at 3.0 T: intraindividual comparative study with MR cholangiopancreatography at 1.5 T for clinical patients. Invest Radiol. 2009;44(9):559\u201365.","journal-title":"Invest Radiol"},{"key":"1184_CR80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejrad.2017.04.009","volume":"92","author":"J Toft","year":"2017","unstructured":"Toft J, et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: a systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol. 2017;92:17\u201323.","journal-title":"Eur J Radiol"},{"issue":"3","key":"1184_CR81","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10689-024-00394-z","volume":"23","author":"B Boekestijn","year":"2024","unstructured":"Boekestijn B, et al. Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions. Fam Cancer. 2024;23(3):295\u2013308.","journal-title":"Fam Cancer"},{"issue":"3","key":"1184_CR82","doi-asserted-by":"publisher","first-page":"802","DOI":"10.2214\/AJR.07.3340","volume":"191","author":"TA Laffan","year":"2008","unstructured":"Laffan TA, et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol. 2008;191(3):802\u20137.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"1184_CR83","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.pan.2017.07.007","volume":"17","author":"M Tanaka","year":"2017","unstructured":"Tanaka M, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738\u201353.","journal-title":"Pancreatology"},{"issue":"1","key":"1184_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djy093","volume":"111","author":"HA Risch","year":"2019","unstructured":"Risch HA. Diabetes and pancreatic cancer: both cause and effect. J Natl Cancer Inst. 2019;111(1):1\u20132.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1184_CR85","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2337\/db16-1477","volume":"66","author":"DK Andersen","year":"2017","unstructured":"Andersen DK, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes. 2017;66(5):1103\u201310.","journal-title":"Diabetes"},{"issue":"7","key":"1184_CR86","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","volume":"156","author":"AD Singhi","year":"2019","unstructured":"Singhi AD, et al. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology. 2019;156(7):2024\u201340.","journal-title":"Gastroenterology"},{"issue":"1","key":"1184_CR87","doi-asserted-by":"publisher","first-page":"50","DOI":"10.6004\/jnccn.2014.0006","volume":"12","author":"KY Fan","year":"2014","unstructured":"Fan KY, et al. Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. J Natl Compr Canc Netw. 2014;12(1):50\u20137.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"1184_CR88","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1097\/MPA.0000000000002335","volume":"53","author":"AM Bogdanski","year":"2024","unstructured":"Bogdanski AM, et al. The added value of blood glucose monitoring in high-risk individuals undergoing pancreatic cancer surveillance. Pancreas. 2024;53(7):e566\u201372.","journal-title":"Pancreas"},{"issue":"14","key":"1184_CR89","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.3390\/cancers15143634","volume":"15","author":"O Partyka","year":"2023","unstructured":"Partyka O, et al. Overview of pancreatic cancer epidemiology in Europe and recommendations for screening in high-risk populations. Cancers. 2023;15(14):3634.","journal-title":"Cancers"},{"key":"1184_CR90","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1245\/s10434-012-2809-1","volume":"20","author":"W Hartwig","year":"2013","unstructured":"Hartwig W, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188\u201396.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1184_CR91","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.gastro.2012.01.005","volume":"142","author":"MI Canto","year":"2012","unstructured":"Canto MI, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4):796\u2013804.","journal-title":"Gastroenterology"},{"issue":"12","key":"1184_CR92","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4240\/wjgs.v12.i12.468","volume":"12","author":"T Lee","year":"2020","unstructured":"Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19\u20139 - tumor marker: Past, present, and future. World J Gastrointest Surg. 2020;12(12):468\u201390.","journal-title":"World J Gastrointest Surg"},{"issue":"6","key":"1184_CR93","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.juro.2010.02.031","volume":"183","author":"AM Kajbafzadeh","year":"2010","unstructured":"Kajbafzadeh AM, et al. Urinary and serum carbohydrate antigen 19\u20139 as a biomarker in ureteropelvic junction obstruction in children. J Urol. 2010;183(6):2353\u201360.","journal-title":"J Urol"},{"issue":"1","key":"1184_CR94","doi-asserted-by":"publisher","first-page":"8820","DOI":"10.1038\/s41598-020-65720-8","volume":"10","author":"S Kim","year":"2020","unstructured":"Kim S, et al. Carbohydrate antigen 19\u20139 elevation without evidence of malignant or pancreatobiliary diseases. Sci Rep. 2020;10(1):8820.","journal-title":"Sci Rep"},{"issue":"5","key":"1184_CR95","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0194599811414512","volume":"145","author":"G Dyckhoff","year":"2011","unstructured":"Dyckhoff G, et al. Carbohydrate antigen 19\u20139 in saliva: possible preoperative marker of malignancy in parotid tumors. Otolaryngol Head Neck Surg. 2011;145(5):772\u20137.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"1184_CR96","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1590\/S1677-5538.IBJU.2013.05.04","volume":"39","author":"S Roy","year":"2013","unstructured":"Roy S, Dasgupta A, Kar K. Comparison of urinary and serum CA 19\u20139 as markers of early stage urothelial carcinoma. Int Braz J Urol. 2013;39(5):631\u20138.","journal-title":"Int Braz J Urol"},{"key":"1184_CR97","doi-asserted-by":"publisher","first-page":"e2300445","DOI":"10.1200\/PO.23.00445","volume":"7","author":"BW Katona","year":"2023","unstructured":"Katona BW, et al. Outcomes of the IMMray PanCan-d test in high-risk individuals undergoing pancreatic surveillance: pragmatic data and lessons learned. JCO Precis Oncol. 2023;7:e2300445.","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"1184_CR98","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1053\/j.gastro.2020.11.052","volume":"160","author":"JF Fahrmann","year":"2021","unstructured":"Fahrmann JF, et al. Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection. Gastroenterology. 2021;160(4):1373-1383.e6.","journal-title":"Gastroenterology"},{"issue":"20","key":"1184_CR99","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1158\/1078-0432.CCR-23-0655","volume":"29","author":"M Dbouk","year":"2023","unstructured":"Dbouk M, et al. Diagnostic performance of a tumor marker gene test to personalize serum CA19-9 reference ranges. Clin Cancer Res. 2023;29(20):4178\u201385.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1184_CR100","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.pan.2016.09.013","volume":"16","author":"G Luo","year":"2016","unstructured":"Luo G, et al. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology. 2016;16(6):1057\u201362.","journal-title":"Pancreatology"},{"issue":"1","key":"1184_CR101","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/2050640615581577","volume":"4","author":"A Wannhoff","year":"2016","unstructured":"Wannhoff A, et al. A common genetic variant of fucosyltransferase 2 correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis. United European Gastroenterol J. 2016;4(1):84\u201391.","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"1184_CR102","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jhep.2013.08.005","volume":"59","author":"A Wannhoff","year":"2013","unstructured":"Wannhoff A, et al. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol. 2013;59(6):1278\u201384.","journal-title":"J Hepatol"},{"issue":"5","key":"1184_CR103","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.cgh.2019.10.036","volume":"18","author":"T Abe","year":"2020","unstructured":"Abe T, et al. Gene variants that affect levels of circulating tumor markers increase identification of patients with pancreatic cancer. Clin Gastroenterol Hepatol. 2020;18(5):1161-1169.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"18","key":"1184_CR104","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1200\/JCO.23.01573","volume":"42","author":"Y Ando","year":"2024","unstructured":"Ando Y, et al. Using tumor marker gene variants to improve the diagnostic accuracy of DUPAN-2 and carbohydrate antigen 19\u20139 for pancreatic cancer. J Clin Oncol. 2024;42(18):2196\u2013206.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1184_CR105","doi-asserted-by":"publisher","first-page":"e00468","DOI":"10.14309\/ctg.0000000000000468","volume":"13","author":"RE Brand","year":"2022","unstructured":"Brand RE, et al. Detection of early-stage pancreatic ductal adenocarcinoma from blood samples: results of a multiplex biomarker signature validation study. Clin Transl Gastroenterol. 2022;13(3):e00468.","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"1184_CR106","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10689-024-00381-4","volume":"23","author":"M Goggins","year":"2024","unstructured":"Goggins M. The role of biomarkers in the early detection of pancreatic cancer. Fam Cancer. 2024;23(3):309\u201322.","journal-title":"Fam Cancer"},{"key":"1184_CR107","unstructured":"Lennon AM, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369(6499)."},{"issue":"10409","key":"1184_CR108","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","volume":"402","author":"D Schrag","year":"2023","unstructured":"Schrag D, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251\u201360.","journal-title":"Lancet"},{"issue":"6378","key":"1184_CR109","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926\u201330.","journal-title":"Science"},{"issue":"9","key":"1184_CR110","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein EA, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167\u201377.","journal-title":"Ann Oncol"},{"issue":"1","key":"1184_CR111","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1038\/s41467-020-18965-w","volume":"11","author":"GD Guler","year":"2020","unstructured":"Guler GD, et al. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA. Nat Commun. 2020;11(1):5270.","journal-title":"Nat Commun"},{"issue":"10","key":"1184_CR112","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/cr.2017.106","volume":"27","author":"CX Song","year":"2017","unstructured":"Song CX, et al. 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Res. 2017;27(10):1231\u201342.","journal-title":"Cell Res"},{"issue":"10","key":"1184_CR113","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/2159-8290.CD-21-1252","volume":"13","author":"AK Mattox","year":"2023","unstructured":"Mattox AK, et al. The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer. Cancer Discov. 2023;13(10):2166\u201379.","journal-title":"Cancer Discov"},{"issue":"8","key":"1184_CR114","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3390\/cancers12082277","volume":"12","author":"HT Chan","year":"2020","unstructured":"Chan HT, et al. Clonal hematopoiesis in liquid biopsy: from biological noise to valuable clinical implications. Cancers (Basel). 2020;12(8):2277.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1184_CR115","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10689-024-00392-1","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, et al. Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer. Fam Cancer. 2024;23(3):351\u201360.","journal-title":"Fam Cancer"},{"issue":"4","key":"1184_CR116","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/MPA.0000000000001268","volume":"48","author":"JE Corral","year":"2019","unstructured":"Corral JE, et al. Cost-effectiveness of pancreatic cancer surveillance in high-risk individuals: an economic analysis. Pancreas. 2019;48(4):526\u201336.","journal-title":"Pancreas"},{"issue":"6","key":"1184_CR117","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/MPA.0000000000001835","volume":"50","author":"S Kumar","year":"2021","unstructured":"Kumar S, et al. Threshold analysis of the cost-effectiveness of endoscopic ultrasound in patients at high risk for pancreatic ductal adenocarcinoma. Pancreas. 2021;50(6):807\u201314.","journal-title":"Pancreas"},{"issue":"17","key":"1184_CR118","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1200\/JCO.2015.64.0730","volume":"34","author":"H Vasen","year":"2016","unstructured":"Vasen H, et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol. 2016;34(17):2010\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1184_CR119","first-page":"739","volume":"119","author":"S Paiella","year":"2024","unstructured":"Paiella S, et al. Outcomes of a 3-year prospective surveillance in individuals at high risk of pancreatic cancer. Am J Gastroenterol. 2024;119(4):739\u201347.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1184_CR120","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1053\/j.gastro.2018.05.035","volume":"155","author":"MI Canto","year":"2018","unstructured":"Canto MI, et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology. 2018;155(3):740-751 e2.","journal-title":"Gastroenterology"},{"issue":"8","key":"1184_CR121","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/jamaoncol.2024.1930","volume":"10","author":"AL Blackford","year":"2024","unstructured":"Blackford AL, et al. Pancreatic cancer surveillance and survival of high-risk individuals. JAMA Oncol. 2024;10(8):1087\u201396.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1184_CR122","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1053\/j.gastro.2021.10.014","volume":"162","author":"KA Overbeek","year":"2022","unstructured":"Overbeek KA, et al. Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. Gastroenterology. 2022;162(3):772-785 e4.","journal-title":"Gastroenterology"},{"issue":"10242","key":"1184_CR123","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008\u201320.","journal-title":"Lancet"},{"issue":"1","key":"1184_CR124","first-page":"37","volume":"279","author":"S Paiella","year":"2024","unstructured":"Paiella S, et al. Surveillance of individuals at high risk of developing pancreatic cancer: a prevalence meta-analysis to estimate the rate of low-yield surgery. Ann Surg. 2024;279(1):37\u201344.","journal-title":"Ann Surg"},{"issue":"5","key":"1184_CR125","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s11605-019-04230-z","volume":"24","author":"MI Canto","year":"2020","unstructured":"Canto MI, et al. Surgical outcomes after pancreatic resection of screening-detected lesions in individuals at high risk for developing pancreatic cancer. J Gastrointest Surg. 2020;24(5):1101\u201310.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"1184_CR126","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10689-016-9930-4","volume":"16","author":"IC Konings","year":"2017","unstructured":"Konings IC, et al. Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance. Fam Cancer. 2017;16(1):143\u201351.","journal-title":"Fam Cancer"},{"issue":"1","key":"1184_CR127","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/cancers16010086","volume":"16","author":"I Anez-Bruzual","year":"2023","unstructured":"Anez-Bruzual I, et al. Assessment of the psychosocial impact of pancreatic cancer surveillance in high-risk individuals. Cancers (Basel). 2023;16(1):86.","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01184-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01184-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01184-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T16:32:27Z","timestamp":1739291547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01184-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01184-1","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"25 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BWK has received clinical trial support from Immunovia and is a member of the scientific advisory board of Immunovia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"61"}}